Journal of immunological methods最新文献

英文中文

A high-throughput assay to measure antibodies that block adhesion of Plasmodium falciparum infected erythrocytes to chondroitin sulfate A. 测定阻断恶性疟原虫感染红细胞对硫酸软骨素A粘附的抗体的高通量测定。

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-12-01 Epub Date: 2025-11-13 DOI: 10.1016/j.jim.2025.114003

Yvonne Dube , Wina Hasang , Andrew Teo , Mwayiwawo Madanitsa , Morten A. Nielsen , Feiko O. Ter Kuile , Elizabeth H. Aitken , Stephen J. Rogerson

Placental malaria due to Plasmodium falciparum (Pf) is associated with adverse pregnancy outcomes. Infected erythrocytes (IEs) bind to placental chondroitin sulfate A (CSA) and antibodies that inhibit this adhesion are a potential correlate of protection. We developed a simplified adhesion inhibition assay that uses diaminofluorene to measure haemoglobin release from IEs bound to CSA.

Using hyperimmune plasma, the assay demonstrated concentration-dependent inhibition of CSA adhesion. Assay performance was consistent over time with strong reproducibility (r = 0.82), and results correlated with a published assay (r = 0.53). In 466 Malawian pregnant women (321 P. falciparum-infected and 145 uninfected at first antenatal visit), adhesion inhibitory antibodies were significantly higher in mid-pregnancy in infected multigravidae (46.3 % IQR 23.2 %, 74.8 %) compared to infected primigravidae (9.7 % IQR 0 %, 29.3 %, p < 0.001) and in uninfected multigravidae (29.9 % IQR 8.6 %, 54.5 %) than uninfected primigravidae (15.6 % IQR 0 %, 36.4 %, p = 0.04). Similar, significant gravidity-dependent differences were observed at delivery in both infected and uninfected women. Between enrolment and delivery, changes in antibodies were similar in infected and uninfected women.

Adhesion inhibitory antibodies protected against placental malaria. Of 162 women with infection at mid-pregnancy, 88 with no placental malaria had more adhesion inhibitory antibody (33.8 %, IQR 1.9 %, 63.2 %) than 74 with past placental malaria (12.5 %, IQR 0 %, 37.8 %; p = 0.002). This low cost, reproducible, and rapid high-throughput adhesion inhibition assay shows promise as a correlate of protection against placental malaria.

恶性疟原虫（Pf）引起的胎盘疟疾与不良妊娠结局有关。受感染的红细胞（IEs）与胎盘硫酸软骨素A （CSA）结合，抑制这种粘附的抗体是保护的潜在关联。我们开发了一种简化的粘附抑制试验，使用二氨基芴来测量与CSA结合的IEs释放的血红蛋白。使用高免疫血浆，实验显示CSA粘附抑制呈浓度依赖性。随着时间的推移，检测性能是一致的，具有很强的重复性（r = 0.82），结果与已发表的检测结果相关（r = 0.53）。在466名马拉维孕妇（321名恶性疟原虫感染和145名首次产前检查未感染）中，妊娠中期感染的多孕科（46.3% % IQR 23.2 %,74.8 %）的粘附抑制抗体明显高于感染的初孕科(9.7% % IQR 0 %,29.3 %,p

{"title":"A high-throughput assay to measure antibodies that block adhesion of Plasmodium falciparum infected erythrocytes to chondroitin sulfate A.","authors":"Yvonne Dube , Wina Hasang , Andrew Teo , Mwayiwawo Madanitsa , Morten A. Nielsen , Feiko O. Ter Kuile , Elizabeth H. Aitken , Stephen J. Rogerson","doi":"10.1016/j.jim.2025.114003","DOIUrl":"10.1016/j.jim.2025.114003","url":null,"abstract":"<div><div>Placental malaria due to <em>Plasmodium falciparum</em> (<em>Pf</em>) is associated with adverse pregnancy outcomes. Infected erythrocytes (IEs) bind to placental chondroitin sulfate A (CSA) and antibodies that inhibit this adhesion are a potential correlate of protection. We developed a simplified adhesion inhibition assay that uses diaminofluorene to measure haemoglobin release from IEs bound to CSA.</div><div>Using hyperimmune plasma, the assay demonstrated concentration-dependent inhibition of CSA adhesion. Assay performance was consistent over time with strong reproducibility (<em>r</em> = 0.82), and results correlated with a published assay (<em>r</em> = 0.53). In 466 Malawian pregnant women (321 <em>P. falciparum</em>-infected and 145 uninfected at first antenatal visit), adhesion inhibitory antibodies were significantly higher in mid-pregnancy in infected multigravidae (46.3 % IQR 23.2 %, 74.8 %) compared to infected primigravidae (9.7 % IQR 0 %, 29.3 %, <em>p</em> < 0.001) and in uninfected multigravidae (29.9 % IQR 8.6 %, 54.5 %) than uninfected primigravidae (15.6 % IQR 0 %, 36.4 %, <em>p</em> = 0.04). Similar, significant gravidity-dependent differences were observed at delivery in both infected and uninfected women. Between enrolment and delivery, changes in antibodies were similar in infected and uninfected women.</div><div>Adhesion inhibitory antibodies protected against placental malaria. Of 162 women with infection at mid-pregnancy, 88 with no placental malaria had more adhesion inhibitory antibody (33.8 %, IQR 1.9 %, 63.2 %) than 74 with past placental malaria (12.5 %, IQR 0 %, 37.8 %; <em>p</em> = 0.002). This low cost, reproducible, and rapid high-throughput adhesion inhibition assay shows promise as a correlate of protection against placental malaria.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"545 ","pages":"Article 114003"},"PeriodicalIF":1.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges limiting the establishment of standardized clinical cutpoints for antibody tests used in the evaluation of hypersensitivity pneumonitis 限制建立用于评估过敏性肺炎的抗体测试的标准化临床切入点的挑战

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113954

Bethany Schuder, Anne Tebo

引用次数: 0

Evolution and characterization of β-Lactam allergy profiles and stability of sIgE over two decades in adult patients 20年来成人患者β-内酰胺过敏谱的演变和特征以及sIgE的稳定性

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113959

Jessica Murphy , Jose-Julio Laguna , Merce Tena , Cosmin Boteanu , Maria-Luisa Sanchez-Millan

引用次数: 0

Donor selection for basophil activation testing 嗜碱性粒细胞激活试验的供体选择

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113944

Renee K. Johnson, Amir A. Sadighi Akha, Attila Kumánovics

引用次数: 0

Going green: boosting efficiency and sustainability with digital solutions 走向绿色：利用数字解决方案提高效率和可持续性

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113958

Jessica Murphy, Phyllis O'Connor

引用次数: 0

Validation of a live cell based assay for the detection of MOG antibodies by flow cytometry 流式细胞术检测MOG抗体的活细胞检测验证

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113938

Conlan Tran

引用次数: 0

Comparative evaluation of pretreatment techniques for enhancing specificity in solid-phase bead-based immunoassays 增强固相珠基免疫测定特异性的预处理技术的比较评价

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113948

Dharmendra Jain , Denise Hurst , Andre Cruz Cruz Delgadillo , Eszter Lázár-Molnár

引用次数: 0

Machine learning can identify an antinuclear antibody pattern that may rule out systemic autoimmune rheumatic diseases 机器学习可以识别抗核抗体模式，可能排除系统性自身免疫性风湿病

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113967

May Y. Choi

引用次数: 0

Determining reference values for the ALZPath plasma p-tau217 assay in a large cohort of elderly individuals with normal cognitive function 确定ALZPath血浆p-tau217测定在一大群认知功能正常的老年人中的参考值

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-28 DOI: 10.1016/j.jim.2025.113930

Pankaj Kumar , Anna Mammel , Ali Mousavi , Mary Encarnacion , Donald Biehl , Hans Frykman

引用次数: 0

Immunogenicity of tislelizumab: clinical summary of ADA incidence and feasibility of assessing the suitability of validation cut points using statistical methods tislelizumab的免疫原性：ADA发病率的临床总结和使用统计方法评估验证切入点适用性的可行性。

IF 1.6 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of immunological methods

Pub Date : 2025-11-01 Epub Date: 2025-10-02 DOI: 10.1016/j.jim.2025.113983

Boxiang Tao , Meng Wang , Yanfei Yang , Na Zhao , Meiling Tan , Xiaolei Xun , Chunxiang Zeng , Fan Wang

Anti-drug antibody (ADA) is a critical indicator of the immunogenicity of biotherapeutics. To investigate the immunogenicity of tislelizumab, a humanized anti-PD-1 (programmed cell death 1) antibody, 3815 patients were analyzed for ADA incidence. The incidence of ADA is reported for the first time as 19.2 %. For any immunogenicity study, appropriate cut points are essential to accurately distinguish true ADA-positive samples from varying backgrounds across populations. Apart from the standardized false positive rate (FPR) method, statistical methods may be more efficient and powerful in evaluating the appropriateness of cut points. However, a detailed protocol for this approach is not yet in consensus. Therefore, by utilizing extensive data from tislelizumab clinical trials, this study explored the feasibility of assessing the suitability of validation cut points (VCPs) using statistical methods. ADA response datasets from 21 clinical tumor populations were evaluated for distribution differences in comparison to the validation population using statistical methods. Fourteen datasets exhibited significant differences from the validation dataset in both medians and variances, with FPRs exceeding the 2–11 % range. Seven datasets only differed significantly in medians, with five having out-of-range FPRs and their positive rates narrowly affected by cut point alteration. The results showed that statistical methods can effectively assess the suitability of VCPs: in-study cut points are recommended for datasets with significantly different median and variance, while VCPs may be appropriate when only medians differ.

抗药抗体（ADA）是生物治疗药物免疫原性的重要指标。为了研究tislelizumab（一种人源抗pd -1（程序性细胞死亡1）抗体）的免疫原性，我们分析了3815例ADA患者的发病率。ADA的发生率首次报道为19.2 %。对于任何免疫原性研究，适当的切点对于准确区分不同背景的人群中真正的ada阳性样本至关重要。除了标准化的假阳性率（FPR）方法外，统计方法在评估切割点的适当性方面可能更有效和强大。然而，这种方法的详细协议尚未达成共识。因此，通过利用tislelizumab临床试验的大量数据，本研究探讨了使用统计方法评估验证切点（VCPs）适用性的可行性。采用统计学方法对21个临床肿瘤人群的ADA应答数据集与验证人群的分布差异进行评估。14个数据集在中位数和方差上都与验证数据集存在显著差异，fpr超过2-11 %的范围。7个数据集仅在中位数上有显著差异，其中5个数据集的fpr超出范围，其阳性率受切点改变的影响很小。结果表明，统计方法可以有效地评估vcp的适用性：对于中位数和方差有显著差异的数据集，建议使用研究中切点，而只有中位数不同时，vcp可能是合适的。

{"title":"Immunogenicity of tislelizumab: clinical summary of ADA incidence and feasibility of assessing the suitability of validation cut points using statistical methods","authors":"Boxiang Tao , Meng Wang , Yanfei Yang , Na Zhao , Meiling Tan , Xiaolei Xun , Chunxiang Zeng , Fan Wang","doi":"10.1016/j.jim.2025.113983","DOIUrl":"10.1016/j.jim.2025.113983","url":null,"abstract":"<div><div>Anti-drug antibody (ADA) is a critical indicator of the immunogenicity of biotherapeutics. To investigate the immunogenicity of tislelizumab, a humanized anti-PD-1 (programmed cell death 1) antibody, 3815 patients were analyzed for ADA incidence. The incidence of ADA is reported for the first time as 19.2 %. For any immunogenicity study, appropriate cut points are essential to accurately distinguish true ADA-positive samples from varying backgrounds across populations. Apart from the standardized false positive rate (FPR) method, statistical methods may be more efficient and powerful in evaluating the appropriateness of cut points. However, a detailed protocol for this approach is not yet in consensus. Therefore, by utilizing extensive data from tislelizumab clinical trials, this study explored the feasibility of assessing the suitability of validation cut points (VCPs) using statistical methods. ADA response datasets from 21 clinical tumor populations were evaluated for distribution differences in comparison to the validation population using statistical methods. Fourteen datasets exhibited significant differences from the validation dataset in both medians and variances, with FPRs exceeding the 2–11 % range. Seven datasets only differed significantly in medians, with five having out-of-range FPRs and their positive rates narrowly affected by cut point alteration. The results showed that statistical methods can effectively assess the suitability of VCPs: in-study cut points are recommended for datasets with significantly different median and variance, while VCPs may be appropriate when only medians differ.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"544 ","pages":"Article 113983"},"PeriodicalIF":1.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of immunological methods

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀